Skip to main content

Bone Marrow Disorders: Drugs

Volume 506: debated on Thursday 4 March 2010

To ask the Secretary of State for Health (1) whether the drug Peginterferon alfa-2a has been approved by the National Institute for Health and Clinical Excellence for use with patients with essential thrombocythaemia; (320596)

(2) which primary care trusts in (a) London and (b) the South East have approved the funding for the treatment of essential thrombocythaemia with Peginterferon alfa-2a.

Peginterferon alfa-2a is not licensed for the treatment of essential thrombocythaemia and the National Institute for Health and Clinical Excellence has not been asked to appraise it for this condition.

Information on primary care trusts' funding decisions is not collected centrally.